Search results for " carriers"

showing 10 items of 283 documents

Inhibition of skin inflammation by baicalin ultradeformable vesicles.

2016

The topical efficacy of baicalin, a natural flavonoid isolated from Scutellaria baicalensis Georgi, which has several beneficial properties, such as antioxidative, antiviral, anti-inflammatory and antiproliferative, is hindered by its poor aqueous solubility and low skin permeability. Therefore, its incorporation into appropriate phospholipid vesicles could be a useful tool to improve its local activity. To this purpose, baicalin at increasing concentrations up to saturation, was incorporated in ultradeformable vesicles, which were small in size (∼67nm), monodispersed (PI<0.19) and biocompatible, regardless of the concentration of baicalin, as confirmed by in vitro studies using fibroblasts…

AdultCell SurvivalSkin AbsorptionPharmaceutical ScienceDermatitis02 engineering and technologyPharmacologyAdministration Cutaneous03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineIn vivomedicineAnimalsHumansDexamethasoneTransdermalFlavonoidsDrug CarriersbiologyEpidermis (botany)Vesicle3T3 CellsMiddle Aged021001 nanoscience & nanotechnologybiology.organism_classificationIn vitrochemistry030220 oncology & carcinogenesisScutellaria baicalensisFemale0210 nano-technologyBaicalinmedicine.drugInternational journal of pharmaceutics
researchProduct

The Influence of Chitosan on the Oral Bioavailability of Acyclovir-a Comparative Bioavailability Study in Humans

2015

Purpose The effects of chitosan hydrochloride on the oral absorption of acyclovir in humans were studied to confirm the absorption enhancing effects reported for in vitro and rat studies, respectively. Methods A controlled, open-label, randomized, 3-phase study was conducted in 12 healthy human volunteers. Zovirax 200 mg dispersible tablets co-administered with doses of 400 and 1000 mg chitosan HCl were compared with Zovirax only. Results The expected increased absorption of acyclovir was not observed. On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and …

AdultMaleBioavailability StudyAcyclovirAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyAbsorption (skin)PharmacologyAntiviral Agents030226 pharmacology & pharmacyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Chitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsbiopharmaceutics classification systemHumansMedicinePharmacology (medical)Chromatography High Pressure LiquidPharmacologyChitosanDrug Carriersbusiness.industryOrganic Chemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverHealthy Volunteers3. Good healthBioavailabilitychemistryexcipient interactionsData Interpretation StatisticalMolecular MedicineFemaleChitosan hydrochloridebioavailability0210 nano-technologybusinesspharmacokineticsResearch PaperBiotechnologyBiological availabilityPharmaceutical Research
researchProduct

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.

2014

In hepatitis B e antigen (HBeAg) positive-HIV co-infected patients treated with combined antiretroviral therapy (cART), including tenofovir disoproxil fumarate (TDF), the rate of HBe seroconversion remains low. Whether adding pegylated interferon alfa (PegIFN) could increase the likelihood of HBeAg loss and HBe seroconversion has not been assessed.A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months. The primary endpoint was HBV sustained response: HBe seroconversion with undetectable HBV DNA levels 24 weeks after completing PegIFN therapy (W72).Fifty-one patients (49 men, median age 46 years, range: 32-6…

AdultMalemedicine.medical_specialtyHBsAgOrganophosphonatesHIV Infectionsmedicine.disease_causeEmtricitabineGastroenterologyAntiviral AgentsDeoxycytidinePolyethylene GlycolsHepatitis B ChronicPegylated interferonInternal medicineAntiretroviral Therapy Highly ActivemedicineEmtricitabineHumansHepatitis B e AntigensSeroconversionTenofovirHepatitis B virusDrug CarriersHepatologybusiness.industryCoinfectionAdeninevirus diseasesLamivudineHIVInterferon-alphaMiddle AgedViral Loaddigestive system diseasesRecombinant ProteinsCD4 Lymphocyte CountTreatment OutcomeHBeAgLamivudineImmunologyFemalebusinessViral loadmedicine.drugJournal of hepatology
researchProduct

Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents

2013

Abstract Background In chronic genotype 1 hepatitis C, telaprevir or boceprevir plus peginterferon and ribavirin have become the new standard of care. Aim of this study was to identify factors contributing to the decision whether to defer or treat with the current triple regimens. Methods Prospective assessment of eight parameters on 0-4-point scales by the attending physician at a German tertiary referral centre between 1st September 2011 and 31st December 2012. Results 307 patients were evaluated at least once by one of the 11 hepatologists involved; 267 patients were considered, but only 163 were recommended to receive triple therapy. Multivariate regression analysis revealed that a high…

AdultMalemedicine.medical_specialtyTime FactorsProlineDecision MakingHepacivirusPharmacologyAntiviral AgentsSeverity of Illness IndexPolyethylene GlycolsTelaprevirCohort Studieschemistry.chemical_compoundFibrosisBoceprevirInternal medicineDrug DiscoveryRibavirinGenotypemedicineHumansDecompensationProspective StudiesWatchful WaitingAgedDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaPatient PreferenceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLogistic ModelschemistryTolerabilityMultivariate AnalysisDisease ProgressionDrug Therapy CombinationFemalebusinessOligopeptidesmedicine.drugDigestive and Liver Disease
researchProduct

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma

2015

Summary What is known and objective Drug eluting beads (DEBs) theoretically improve the efficacy and safety of transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC). Nonetheless, their economic profile has not been assessed. Our retrospective before/after study aimed to compare efficacy, safety and economic profile of two strategies of TACE without (Period 1) or with the possibility of using DEBs (Period 2). Methods All HCC patients treated by TACE in our hospital between March 2006 and May 2013 were included. Economic analyses were performed from the French Public Health Insurance point of view according to the French Diagnosis-Related Group prospective payment system an…

AdultMalesafetymedicine.medical_specialtyCarcinoma HepatocellularCost effectivenesschemoembolisationCost-Benefit AnalysisAntineoplastic AgentsTreatment failureDrug CostsEthiodized OilInternal medicinemedicineOverall survivalHumansPharmacology (medical)Chemoembolization Therapeuticcost-effectivenessAgedRetrospective StudiesPharmacologyAged 80 and overDrug CarriersDrug eluting beadsPublic health insurancebusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisMicrospheres3. Good healthSurgerySurvival RateTreatment OutcomeMedian timeDoxorubicinHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyFemaleProspective payment systembusinessIdarubicin
researchProduct

Targeted Hybrid Nanocarriers as a System Enhancing the Skin Structure

2021

The skin is constantly exposed to external and internal factors that disturb its function. In this work, two nanosystems-levan nanoparticles and a surfactin-stabilized nanoemulsion were preserved (tested for microbial growth) and characterized (size, polydispersity, Zeta potential, and stability). The nanosystems were introduced in the model formulations-cream, tonic, and gel, and confirmed by TEM. The analysis showed that nanoemulsion has a spherical morphology and size 220–300 nm, while levan nanoparticles had irregular shapes independently of the use of matrix and with particle size (130–260 nm). Additionally, we examined the antiradical effect of levan nanoparticles and nanoemulsion in …

AdultskinMaterials scienceDPPHDispersitySkin CreamnanoemulsionPharmaceutical ScienceNanoparticleformulationMicrobial Sensitivity Tests02 engineering and technology030226 pharmacology & pharmacySkin DiscolorationsurfactinArticleAnalytical Chemistrylcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinelcsh:Organic chemistryIn vivoDrug DiscoveryZeta potentialHumansPhysical and Theoretical ChemistryDrug CarriersBacteriaanti-agingOrganic ChemistryMiddle Aged021001 nanoscience & nanotechnologyDynamic Light ScatteringlevanFructansSkin AgingchemistryChemistry (miscellaneous)Molecular MedicineEmulsionsFemalenanoparticlesParticle sizeNanocarriers0210 nano-technologyBiomedical engineeringMolecules
researchProduct

Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens

2013

Carbon nanotubes (CNTs) are nanomaterials with interesting emerging applications. Their properties make CNTs excellent candidates for use as new nanovehicles in drug delivery, immunization and diagnostics. In the current study, we assessed the immune-response-amplifying properties of CNTs to haptens by using azoxystrobin, the first developed strobilurin fungicide, asamodel analyte. Anazoxystrobin derivative bearingacarboxylated spacer arm (hapten AZc6) was covalently coupled to bovine serum albumin (BSA), and the resulting BSA-AZc6 conjugate was covalently linked to four functionalized CNTs of different shapes and sizes, varying in diameter and length. These four types of CNT-based construc…

Analytemedicine.medical_treatmentAzoxystrobinFreund's AdjuvantAntigen deliveryCarbon nanotubesPharmaceutical ScienceAntibodiesBiomaterialsMicechemistry.chemical_compoundMicroscopy Electron TransmissionmedicineAnimalsOrganic chemistryBovine serum albuminDrug CarriersMice Inbred BALB CbiologyNanotubes CarbonChemistrySerum Albumin BovineStrobilurinsFungicides IndustrialPyrimidinesAzoxystrobinImmunoglobulin GDrug deliverybiology.proteinBiophysicsMethacrylatesFemaleImmunizationRabbitsAntibodyHaptensAdjuvantHaptenConjugate
researchProduct

Sterically geared tris-thioureas; transmembrane chloride transporters with unusual activity and accessibility

2015

Tris-N-arylthioureas derived in one step from 1,3,5-tris(aminomethyl)-2,4,6-triethylbenzene are remarkably effective anion carriers. With optimised aryl substituents their activities come close to the best currently known, suggesting that they might find use as readily available standards in anion transport research.

AnionsModels MolecularTrisSteric effectsCrystallography X-RayChlorideCatalysisPhysico-chimie généralechemistry.chemical_compoundChloridesMaterials ChemistrymedicineChimieMoleculeOrganic chemistryta116Ion transporterIon TransportMolecular StructureChemistryArylThioureatransmembrane anion carriersMetals and Alloystransmembrane transportersGeneral ChemistryCombinatorial chemistryTransmembrane proteinSurfaces Coatings and FilmsElectronic Optical and Magnetic MaterialsChimie organiqueThioureaCeramics and Compositesmedicine.drugChemical Communications
researchProduct

Biomedical Applications of Polylactide (PLA) and Its Copolymers.

2018

n/a

Anti-Infective AgentPolyestersMicrofluidicsPolyesterPharmaceutical ScienceBiocompatible Materials02 engineering and technology01 natural sciencesAnalytical ChemistryPolymerizationlcsh:QD241-441Nanoparticlelcsh:Organic chemistryAnti-Infective AgentsDrug DiscoveryCopolymerHumansPhysical and Theoretical ChemistryDrug CarrierBiocompatible MaterialDrug CarriersPolymer scienceTissue Scaffolds010405 organic chemistryChemistryOrganic Chemistry021001 nanoscience & nanotechnologyBone Diseases Infectious0104 chemical sciencesBone Diseases Infectioun/aEditorialMicrofluidicChemistry (miscellaneous)PeptideMolecular MedicineNanoparticles0210 nano-technologyPeptidesHumanMolecules (Basel, Switzerland)
researchProduct

Polyaspartylhydrazide Copolymer-Based Supramolecular Vesicular Aggregates as Delivery Devices for Anticancer Drugs

2008

In this paper we report on three different hydrophilic copolymers based on alpha,beta-polyaspartylhydrazide (PAHy) bearing butyric groups in the side chain (C 4) (PAHy-C 4) or a combination of butyric groups and positive charged residues ((carboxypropyl)trimethylammonium chloride, CPTACl) (PAHy-C 4-CPTA) that were synthesized and used for the preparation of new supramolecular vesicular aggregates (SVAs) containing gemcitabine as an antitumor drug. Gemcitabine-loaded SVAs containing synthesized PAHy derivatives were characterized from the physicochemical and technological point of view and the in vitro toxicity and anticancer activity on two different human cancer cell lines, i.e., CaCo-2 (h…

Antimetabolites AntineoplasticMagnetic Resonance SpectroscopyPolymers and PlasticsPolymerssupramolecular aggregates polyaspartylhydrazide copolymersSupramolecular chemistryApoptosisBioengineeringDeoxycytidineBiomaterialsButyric acidchemistry.chemical_compoundDrug Delivery SystemsTumor Cells CulturedMaterials ChemistrySide chainCopolymerHumansThyroid NeoplasmsCytotoxicityCells CulturedChromatography High Pressure LiquidDrug CarriersMolecular StructureChemistryVesicleFlow CytometryGemcitabineIn vitroBiochemistryColonic NeoplasmsChromatography GelPeptidesDrug carrierBiomacromolecules
researchProduct